3rd Quarter - Report

ALLERGAN, INC. for ALLERGAN, INC.

Period 3rd Quarter 2013 Filed Oct 21, 2013 Signed by JENNIE UNGER SKELTON, ATTORNEY & AGENT FOR FILER

Official filing
Firm
ALLERGAN, INC.
Client
ALLERGAN, INC.
Income
—
Expenses
$320,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

NO SPECIFIC BILL: ENFORCEMENT OF FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS NO SPECIFIC BILL: REGULATION OF BIOSIMILAR NEUROMODULATOR PRODUCTS NO SPECIFIC BILL: GOVERNMENT REIMBURSEMENT ISSUES UNDER FEDERAL HEALTHCARE PLANS NO SPECIFIC BILL: FOOD AND DRUG ADMINISTRATION (FDA) DRAFT GUIDANCE REGARDING BIOEQUIVALENCENO SPECIFIC BILL: 340 B DRUG DISCOUNT PROGRAM REFORM NO SPECIFIC BILL: SAFETY ISSUES NO SPECIFIC BILL: TAX REFORM

LobbyistCovered position, as disclosed
EDWARD C RENO N/A

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.